Tampere University Hospital | Tampere Heart Hospital
Status and phase
Conditions
Treatments
About
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
654 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Incyte Corporation Call Center (ex-US); Incyte Corporation Call Center (US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal